TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22545165

Group type: EXPERIMENTAL
Intervention: Presence of facial flies
Number of subjects: 24536

Group type: EXPERIMENTAL
Intervention: Years of formal education completed by the head of household
Number of subjects: 24536

Group type: EXPERIMENTAL
Intervention: Nasal discharge
Number of subjects: 24536

Group type: EXPERIMENTAL
Intervention: Presence of flies on the face
Number of subjects: 24536
Study: 19624626

Group type: EXPERIMENTAL
Intervention: Remifentanil 4.0 microg.kg(‐1) co-administered with propofol 2.5 mg.kg(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Remifentanil 1, 2, 3, 4, or 5 microg.kg(‐1) co-administered with propofol 2.5 mg.kg(‐1)
Number of subjects: 90
Study: 17332198

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Codeine (1 mg/kg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Acetaminophen (15 mg/kg)
Number of subjects: 300
Study: 15492182

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-enriched cellular graft applied to one lesion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo applied to the paired lesion
Number of subjects: 28
Study: 11767272

Group type: EXPERIMENTAL
Intervention: Topical application of physostigmine (100 microl, 2-8 mg/ml) for 1 min in healthy subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mouth rinse solution of physostigmine (10 ml, 0.4-1.6 mg/ml) for 2 min in dry-mouth patients
Number of subjects: 20
Study: 9247512

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation present
Number of subjects: 40381
Study: 8516307

Group type: EXPERIMENTAL
Intervention: L‐697,661 25 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L‐697,661 100 mg three times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L‐697,661 500 mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine 100 mg five times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L‐697,661
Number of subjects: 0
Study: 3802717

Group type: COMPARATOR
Intervention: Acute ethanol administration
Number of subjects: 0
Study: 29701039

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhiyang (GV 9) Bazhen points combined with pantoprazole (40 mg once a day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Pantoprazole (40 mg once a day)
Number of subjects: 102
Study: 26684478

Group type: EXPERIMENTAL
Intervention: Adapted Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 300

Group type: COMPARATOR
Intervention: Health Education (Healthy Topics [HT]) program
Number of subjects: 300
Study: 25666481

Group type: EXPERIMENTAL
Intervention: Early amniotomy (artificial amniotomy at cervical dilation <4 cm)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine management (control group)
Number of subjects: 300
Study: 23521561

Group type: EXPERIMENTAL
Intervention: Humectant-rich formulation (15% alfahydroxy acids and 15% urea) applied once and twice daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 62
Study: 19882105

Group type: EXPERIMENTAL
Intervention: Combined TURP and inguinal hernioplasty in the same session (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TURP followed by inguinal hernioplasty in separate sessions (Group II)
Number of subjects: 30
Study: 18194559

Group type: EXPERIMENTAL
Intervention: Agenda-setting intervention for physicians
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group physicians
Number of subjects: 21
Study: 16766606

Group type: EXPERIMENTAL
Intervention: Recruitment strategies involving both partners simultaneously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment teams consisting of men and women
Number of subjects: 0
Study: 12955553

Group type: EXPERIMENTAL
Intervention: Essential hyperhidrosis patients (EH)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Controls with normal ANS function
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Essential hyperhidrosis patients (EH) during tilt test
Number of subjects: 19

Group type: COMPARATOR
Intervention: Controls during tilt test
Number of subjects: 19
Study: 10968851

Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 67
Study: 9343031

Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 274

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 274
Study: 8372265

Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous diclofenac
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 2425755

Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 19

Group type: COMPARATOR
Intervention: UVA plus placebo
Number of subjects: 19
Study: 31599084

Group type: EXPERIMENTAL
Intervention: Vasopressor infusion via peripheral venous catheters (PVC)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Vasopressor infusion via central venous catheters (CVC)
Number of subjects: 937
Study: 30364005

Group type: EXPERIMENTAL
Intervention: GWG intervention based on an energy balance model
Number of subjects: 17
Study: 27881335

Group type: EXPERIMENTAL
Intervention: Health Qigong Wuqinxi training for 12 weeks
Number of subjects: 58
Study: 24216342

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact immediately after birth
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 114
Study: 22516476

Group type: EXPERIMENTAL
Intervention: Assist Control Ventilation (ACV)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 36
Study: 21316535

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) administered with a 2-week interval between doses
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) administered with a 3-week interval between doses
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) administered with a 6-week interval between doses
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) with a 2-week interval
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) with a 3-week interval
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses)
Number of subjects: 240
Study: 17977472

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 15505873

Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening for AAA
Number of subjects: 67800

Group type: COMPARATOR
Intervention: Control group (no invitation for screening)
Number of subjects: 67800
Study: 11765544

Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 157
Study: 9509206

Group type: EXPERIMENTAL
Intervention: 1000 ml of compound sodium lactate solution during surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intraoperative fluid
Number of subjects: 100
Study: 7528160

Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution (HHD): Infusion of 15 ml/kg bodyweight hydroxyethyl starch (200/0.5)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Acute normovolemic hemodilution (ANH): Withdrawal of 15 ml/kg bodyweight autologous blood and isovolemic replacement by hydroxyethyl starch (200/0.5)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution (HHD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 49
Study: 2494454

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 million units over 30 minutes)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA) (100 mg over three hours)
Number of subjects: 270
Study: 8507540

Group type: EXPERIMENTAL
Intervention: PAC plus SPG combination therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: PAC therapy
Number of subjects: 68
Study: 391258

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study: 30621742

Group type: EXPERIMENTAL
Intervention: Single-shot sciatic nerve block with 2 mg/ml ropivacaine, 20 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: No sciatic nerve block
Number of subjects: 40
Study: 28383451

Group type: EXPERIMENTAL
Intervention: Karydakis procedure with tie‐over compressing sutures without a drain
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard Karydakis procedure
Number of subjects: 154
Study: 26370384

Group type: EXPERIMENTAL
Intervention: Preformed metal crowns placed using a polyvinyl siloxane occlusal template
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preformed metal crowns placed without the use of an occlusal template (Control)
Number of subjects: 60
Study: 23399660

Group type: EXPERIMENTAL
Intervention: MyPyramid and supplementary information about n-3 fatty acids
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (MyPyramid only)
Number of subjects: 88
Study: 21422239

Group type: EXPERIMENTAL
Intervention: Sodium 2,2 dimethylbutyrate (SDMB) at doses of 2, 5, 10, and 20 mg/kg single dose or 5, 10, or 15 mg/kg daily for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19972627

Group type: EXPERIMENTAL
Intervention: LP-1 (last positive stage of the Talk Test)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LP (last positive stage of the Talk Test)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: EQ (first equivocal stage of the Talk Test)
Number of subjects: 14
Study: 17716544

Group type: EXPERIMENTAL
Intervention: Tomato-rich diet (300 g tomatoes daily for 1 month)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control diet (usual diet with tomatoes prohibited for 1 month)
Number of subjects: 103
Study: 15049460

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control (non-supplementation)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Geophageous children
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Geophageous children with Hb < 130 g/l
Number of subjects: 406
Study: 11682413

Group type: EXPERIMENTAL
Intervention: Ropivacaine (scalp block with 20 mL of ropivacaine 0.75%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (scalp block with 20 mL of saline 0.9%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 9490235

Group type: EXPERIMENTAL
Intervention: Baseline levels of C-reactive protein (CRP)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Quartiles of baseline CRP concentration
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Baseline CRP levels in case patients requiring revascularization
Number of subjects: 144
Study: 8313128

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 61

Group type: COMPARATOR
Intervention: Angelchik prosthesis
Number of subjects: 61
Study: 2901611

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus preparation for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study: 30968820

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) for 2 years
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ad libitum diet (AL)
Number of subjects: 220
Study: 31017639

Group type: EXPERIMENTAL
Intervention: Integrated Prolonged Exposure (I-PE) therapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Integrated Coping Skills (I-CS) therapy
Number of subjects: 119
Study: 28318759

Group type: EXPERIMENTAL
Intervention: Asthma, Sport and Health (ASAH) programme
Number of subjects: 203

Group type: COMPARATOR
Intervention: Comparison School (CS)
Number of subjects: 203
Study: 26236997

Group type: EXPERIMENTAL
Intervention: egg oral immunotherapy (egg‐OIT) for 3 months (maintenance dose one undercooked egg every 48 hours)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (CG) continued egg avoidance diet for 4 months
Number of subjects: 61
Study: 23324689

Group type: EXPERIMENTAL
Intervention: ReDO programme (16-week work rehabilitation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 42
Study: 20849371

Group type: EXPERIMENTAL
Intervention: NUTRIOSE®FB10
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 12
Study: 18074149

Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg once daily for 14 days)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Ceftriaxone (50 mg/kg once daily for 3 days) followed by Ceftibuten (for 11 days)
Number of subjects: 365
Study: 17044843

Group type: EXPERIMENTAL
Intervention: Triptans (specifically naratriptan, frovatriptan, zolmitriptan)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Naproxen sodium, magnesium
Number of subjects: 35
Study: 12650133

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg thrice weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11557471

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Gatifloxacin
Number of subjects: 58
Study: 9756240

Group type: EXPERIMENTAL
Intervention: rhGH (1 U/kg IBW/week in daily subcutaneous injections)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 20
Study: 8123235

Group type: EXPERIMENTAL
Intervention: Surgical salvage following radiotherapy failure
Number of subjects: 88

Group type: COMPARATOR
Intervention: Primary radiotherapy with surgery reserved for radiotherapy failures
Number of subjects: 88
Study: 3051550

Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine and dapsone) administered fortnightly for 2 years
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine and dapsone)
Number of subjects: 48
Study: 30612585

Group type: EXPERIMENTAL
Intervention: Burnaid® hydrogel dressing
Number of subjects: 72

Group type: COMPARATOR
Intervention: Plastic wrap (control)
Number of subjects: 72
Study: 29645411

Group type: EXPERIMENTAL
Intervention: Lecture combined with using a smartphone application
Number of subjects: 673

Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Participants doing research projects
Number of subjects: 673
Study: 25003624

Group type: EXPERIMENTAL
Intervention: Soy isoflavones 80 mg/day
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Soy isoflavones 120 mg/day
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 224
Study: 23605375

Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (non-treatment)
Number of subjects: 17
Study: 22097197

Group type: EXPERIMENTAL
Intervention: Safflower Injection (20 mL in 250 mL 5% glucose injection, administered intravenously once per day for 1-7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dextran-40 (administered intravenously once per day for 1-7 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Safflower Injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dextran-40
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 19756528

Group type: EXPERIMENTAL
Intervention: DMAE p-Glu
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 0
Study: 16838647

Group type: EXPERIMENTAL
Intervention: Interferon as maintenance therapy following chemotherapy or autologous stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon therapy during induction therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon as maintenance therapy for patients responding to first-line therapy
Number of subjects: 0
Study: 14738559

Group type: EXPERIMENTAL
Intervention: Induction therapy with 6 MU IFN alpha daily for 6 weeks, followed by 6 MU three times a week for 18 weeks and then 3 MU three times a week until week 48, plus ribavirin (10 mg/kg/day) and amantadine (200 mg/day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard therapy with 6 MU IFN alpha three times a week for 24 weeks, followed by 3 MU until week 48, plus ribavirin (10 mg/kg/day) and amantadine (200 mg/day)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Induction therapy with 6 MU IFN alpha daily
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard therapy with 6 MU IFN alpha three times a week
Number of subjects: 158
Study: 11530657

Group type: EXPERIMENTAL
Intervention: Behavioral intervention targeting three diabetes-related behaviors
Number of subjects: 0
Study: 9350914

Group type: EXPERIMENTAL
Intervention: Verapamil (0.5 mg) injected into the infarct-related artery shortly after PTCA, followed by oral administration.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (PTCA alone)
Number of subjects: 40
Study: 7900949

Group type: EXPERIMENTAL
Intervention: 500 mg/day zidovudine
Number of subjects: 1423

Group type: EXPERIMENTAL
Intervention: 1500 mg/day zidovudine
Number of subjects: 1423

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1423
Study: 3096626

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aurothioglucose
Number of subjects: 40
Study: 30588201

Group type: EXPERIMENTAL
Intervention: Eccentric Exercise (EE) with Vibration training for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Eccentric Exercise (EE) with Cryotherapy for 12 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (EE with Vibration and EE with Cryotherapy)
Number of subjects: 61
Study: 26714179

Group type: EXPERIMENTAL
Intervention: Postoperative care with frequent followup by a care navigator
Number of subjects: 308

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 308
Study: 25268567

Group type: EXPERIMENTAL
Intervention: High-dose progesterone (PG)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: E2 supplementation
Number of subjects: 360

Group type: COMPARATOR
Intervention: Low-dose progesterone (PG)
Number of subjects: 360
Study: 22612244

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 94
Study: 20485337

Group type: EXPERIMENTAL
Intervention: 160 mg D,L‐sotalol
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 320 mg D,L‐sotalol
Number of subjects: 83

Group type: COMPARATOR
Intervention: moxifloxacin
Number of subjects: 83

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study: 18584369

Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin (2.5, 5, 7.5, or 10 g) administered intravenously over 7.5 to 30 minutes
Number of subjects: 41
Study: 16221780

Group type: EXPERIMENTAL
Intervention: Whole-body cooling to an esophageal temperature of 33.5 degrees C for 72 hours
Number of subjects: 239

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 239
Study: 11840792

Group type: EXPERIMENTAL
Intervention: Intracameral anesthesia with 0.15 ml lidocaine 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sponge anesthesia without lidocaine
Number of subjects: 40
Study: 10512276

Group type: EXPERIMENTAL
Intervention: 15 mg/kg phenytoin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7736649

Group type: EXPERIMENTAL
Intervention: Pure FSH (Metrodin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional gonadotropin (Pergonal)
Number of subjects: 30
Study: 1999714

Group type: EXPERIMENTAL
Intervention: VMCP/VBAP
Number of subjects: 304

Group type: COMPARATOR
Intervention: MP
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: LI >= 2%
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: beta 2-m >= 6 mg/L
Number of subjects: 304
Study: 6825391

Group type: EXPERIMENTAL
Intervention: 600 mg Asproclear
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 600 mg Bufferin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 600 mg Bi-prin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 600 mg compressed ASA
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 650 mg Ecotrin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 650 mg S.R.A.
Number of subjects: 6
Study: 31476451

Group type: EXPERIMENTAL
Intervention: Fish oil (2.5 g/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 28634644

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 267
Study: 27076592

Group type: EXPERIMENTAL
Intervention: Total and exclusive breastfeeding
Number of subjects: 620
Study: 24994919

Group type: EXPERIMENTAL
Intervention: Oxygen administered via nasal cannula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air administered via nasal cannula
Number of subjects: 0
Study: 22822043

Group type: EXPERIMENTAL
Intervention: Colloid solution (15 ml kg(‐1) over 30 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Crystalloid solution (15 ml kg(‐1) over 30 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both interventions (steady-state and dynamic phases)
Number of subjects: 30
Study: 20354559

Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient supplementation (micronutrient powder, syrup, and milk-based fortified-food supplement)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Micronutrient-only group (MM)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Fortified-food supplement (FFS)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Comparison group (no supplementation)
Number of subjects: 187
Study: 19012672

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (10 weeks, 3 days a week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 30
Study: 15963096

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg once daily for 4 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg once daily for 4 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (150 microg oral dose of desogestrel alone)
Number of subjects: 11